Palatin Technologies to raise $15.8m in public offering; NYSE relisting expected Nov 12

Palatin Technologies, Inc. has announced the pricing of a $15.8 million underwritten public offering, timed just ahead of its planned Investigational New Drug (IND) submission for PL7737, an oral melanocortin-4 receptor (MC4R) agonist designed to treat obesity. The fundraising is structured to provide near-term capital for Palatin Technologies’ obesity program and other general working capital needs while enabling the biopharmaceutical firm to regain compliance with the NYSE American exchange listing requirements. The company’s stock is expected to resume trading on the NYSE American under the symbol “PTN” beginning November 12, 2025.

The offering includes 2,430,769 shares of common stock, or pre-funded warrants in lieu of shares, bundled with Series J and Series K milestone-based warrants. The combined offering price was set at USD 6.50 per share with each unit including both classes of warrants. The gross proceeds, prior to deductions for underwriting discounts and expenses, are projected at approximately USD 15.8 million. Palatin Technologies has also granted underwriters a 45-day option to purchase an additional 364,615 shares at the same terms.

The financing round was led by healthcare-focused institutional investors and also included participation from key executives such as the Chief Executive Officer and Chief Financial Officer, as well as several board members. Their direct involvement reinforces internal confidence in the near-term clinical development timeline and broader market opportunity.

The capital raise comes at a critical inflection point for Palatin Technologies. The company is preparing to file an IND with the United States Food and Drug Administration for PL7737 and plans to initiate a Phase 1 single and multiple ascending dose study in the first half of 2026. Success at this stage would move Palatin Technologies into the increasingly competitive but high-growth obesity therapeutics space, which has been dominated by incretin-based therapies from larger pharmaceutical companies.

How do the Series J and Series K warrants reflect Palatin Technologies’ milestone-linked upside strategy?

The Series J and Series K warrants embedded within the financing are directly tied to Palatin Technologies’ regulatory and clinical milestones. Each Series J warrant is exercisable at USD 6.50 and becomes active immediately. These warrants will expire either on the 18-month anniversary of the original issue date or on the 31st calendar day following FDA acceptance of the IND application for an in-house obesity therapy, whichever comes first. This structure creates a built-in incentive for early exercise upon regulatory progression.

The Series K warrants are priced at USD 8.125 and carry a five-year expiration term. However, if Series J warrants are still valid past the FDA acceptance window, the Series K warrants will terminate early—either at the end of the Series J timeline or the FDA milestone date. This layered design provides both downside protection and upside optionality, aligning capital deployment with Palatin Technologies’ pipeline execution.

Should the Series J warrants be exercised in full, Palatin Technologies could raise an additional USD 15.8 million. However, as with all milestone-linked warrants, there is no guarantee that the FDA milestone will be met or that holders will exercise the warrants. The financing framework signals to investors that Palatin Technologies is closely aligning capital flows with key clinical development events.

What are the implications of Palatin Technologies’ NYSE American relisting and regulatory compliance?

Palatin Technologies had fallen below the NYSE American’s stockholders’ equity requirements under Section 1003(a)(iii), prompting its shares to be temporarily shifted to over-the-counter trading. The completion of this USD 15.8 million offering allows the company to regain compliance with the exchange’s continued listing standards. Trading on NYSE American is expected to resume effective November 12, 2025, under the ticker symbol “PTN” and CUSIP 696077601.

The relisting is a significant milestone for investor confidence. Institutional and retail investors typically regard NYSE American-listed stocks with greater credibility and liquidity access than OTC securities. The shift back to a national exchange also broadens potential inclusion in small-cap and biotech-focused indexes and improves screening eligibility for passive investment strategies.

Palatin Technologies’ decision to time its fundraising with relisting shows a coordinated strategic approach aimed at both restoring visibility in public markets and signaling operational readiness for its next clinical stage.

What is the development status of PL7737 and how does it compare with GLP-1 competitors?

Palatin Technologies is advancing PL7737 as a differentiated obesity treatment built on selective activation of the MC4R pathway. Unlike GLP-1 receptor agonists such as semaglutide or tirzepatide, which function through incretin modulation and pancreatic insulin signaling, MC4R agonists target appetite and energy regulation via the hypothalamus.

The company recently reported strong preclinical results in a rodent model of diet-induced obesity. PL7737 demonstrated up to 10 percent weight loss after just four days of treatment as a monotherapy, and up to 15 percent when combined with tirzepatide. These findings were statistically significant and suggest potential additive effects when pairing MC4R agonists with existing incretin-based therapies.

Palatin Technologies has positioned PL7737 as both a standalone oral therapy and a potential combo agent. The drug is also being developed for rare subtypes of obesity such as hypothalamic obesity and leptin receptor (LEPR) deficiency. Earlier this year, PL7737 received orphan drug designation from the FDA for LEPR deficiency-related obesity, adding potential regulatory incentives and market exclusivity.

The IND-enabling toxicology studies for PL7737 are currently ongoing. The company anticipates filing an IND in the fourth quarter of 2025, with clinical data from a Phase 1 study expected in the first half of 2026. A second candidate, a long-acting peptide MC4R agonist for weekly injection, is also in advanced preclinical development.

How is Palatin Technologies expanding its platform beyond obesity through the Boehringer Ingelheim partnership?

In August 2025, Palatin Technologies entered into a strategic research collaboration with Boehringer Ingelheim focused on retinal diseases, including diabetic retinopathy and diabetic macular edema. The partnership aims to co-develop first-in-class treatments targeting melanocortin receptors in the eye. The deal includes an upfront payment of EUR 2 million (USD 2.3 million) and milestone potential up to EUR 278 million (USD 328 million), plus royalties on future net sales.

In September 2025, Palatin Technologies achieved a key research milestone under the agreement, triggering a EUR 5.5 million (USD 6.5 million) milestone payment. The milestone recognition confirmed early progress in the collaboration and offered Palatin Technologies a non-dilutive capital source alongside its equity raise.

The Boehringer partnership underscores the broad potential of Palatin Technologies’ MC4R platform. While obesity remains the near-term focus, applications in inflammation, immune modulation, and ophthalmic conditions offer diversification and risk mitigation. Institutional investors have noted that platform companies with dual-path pipelines often trade at premium valuations compared to single-asset biotech firms.

What is the current investor sentiment around Palatin Technologies following the equity raise and pipeline updates?

Investor sentiment around Palatin Technologies remains mixed but is showing signs of stabilization following the public offering announcement. Prior to the offering, the company’s shares had been under pressure due to delisting risks and limited near-term visibility. The successful raise and confirmed NYSE American relisting have eased those concerns and opened up broader participation from institutional investors.

The market is now closely watching the IND timing for PL7737 and early clinical safety data. The stock’s milestone-linked warrant structure is being interpreted by analysts as a signal of regulatory confidence, though near-term volatility is likely to persist until Phase 1 data is available.

Analysts and sector watchers note that Palatin Technologies could attract more institutional flows if it continues to deliver on clinical timelines, especially with both obesity and rare disease applications in play. While the obesity market is increasingly competitive, the MC4R agonist mechanism offers a unique pathway that could allow Palatin Technologies to differentiate itself from GLP-1 incumbents.

What lies ahead for Palatin Technologies as it prepares for clinical entry in 2026?

With the proceeds from the public offering and milestone payment from Boehringer Ingelheim, Palatin Technologies is financially positioned to enter a new clinical execution phase. The company plans to initiate first-in-human trials for both oral and long-acting peptide MC4R agonists in the first half of 2026. These trials will provide key safety, tolerability, and early efficacy signals.

Success in early trials could accelerate licensing discussions, attract further strategic partnerships, or enable additional non-dilutive capital raises. The firm’s FDA orphan designation for PL7737 in LEPR deficiency also provides a regulatory runway for expedited development in a niche patient population.

For investors, the next six to nine months represent a critical validation window. Regulatory acceptance of the IND, successful relisting, and progression into clinical development would mark Palatin Technologies as a legitimate contender in the metabolic disease and rare obesity space.

What are the key takeaways from Palatin Technologies’ offering, relisting, and obesity drug pipeline?

• Palatin Technologies has priced a USD 15.8 million public offering to fund its upcoming IND submission for PL7737, an oral MC4R agonist being developed for obesity and rare genetic disorders like LEPR deficiency.

• The offering includes Series J and Series K milestone-based warrants, with the potential to raise an additional USD 15.8 million if Series J warrants are exercised upon FDA acceptance of the IND.

• The offering has not yet closed; it is expected to close on or around November 12, 2025, pending customary conditions, including the resumption of trading on the NYSE American under the ticker “PTN.”

• PL7737 has demonstrated strong preclinical efficacy, showing up to 15 percent weight loss in rodent models when combined with tirzepatide, supporting differentiation from GLP-1/GIP therapies.

• Palatin Technologies also reported a USD 6.5 million milestone payment from Boehringer Ingelheim under a partnership targeting retinal diseases like diabetic retinopathy, adding non-dilutive capital and validation of its melanocortin receptor platform.

• The company aims to begin Phase 1 trials for both oral and long-acting peptide MC4R candidates in the first half of 2026, with IND submission for PL7737 expected by the end of 2025.

• Relisting on the NYSE American will restore visibility among institutional investors, improve liquidity, and may unlock index eligibility for biotech and small-cap funds.